NCT02609659View on ClinicalTrials.gov

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

October 28, 2015

Primary Completion Date

October 7, 2016

Study Completion Date

December 28, 2016

Conditions
Hepatitis C Virus (HCV)
Interventions
DRUG

ombitasvir/paritaprevir/ritonavir and dasabuvir

Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

DRUG

ribavirin

Tablet

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY